CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma

被引：0

作者：

Zi, Dan ^{[1
,2
,3
,4
,5
,6
]}

Li, Qing ^{[7
,8
,10
]}

Xu, Cheng-xiong ^{[7
,8
,10
]}

Zhou, Zhi-Wei ^{[9
]}

Song, Guan-Bin ^{[9
]}

Hu, Cheng-Bin ^{[11
]}

Wen, Fang ^{[2
]}

Yang, Han-Lin ^{[2
]}

Nie, Lei ^{[2
]}

Zhao, Xing ^{[3
]}

Tan, Jun ^{[4
,5
]}

Zhou, Shu-Feng ^{[6
,12
]}

He, Zhi-Xu ^{[3
,13
]}

机构：

[1] Guizhou Prov Peoples Hosp, Dept Obstet & Gynecol, Guiyang 550002, Guizhou, Peoples R China

[2] Guizhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp, Guiyang 550004, Peoples R China

[3] Guizhou Med Univ, Guizhou Med Univ, Key Lab Adult Stem Cell Transformat Res, Stem Cell & Tissue Engn Res Ctr, Guiyang 550004, Peoples R China

[4] Guizhou Med Univ, Key Lab Endem & Ethn Dis, Minist Educ, Key Lab Mol Biol, Guiyang 550004, Peoples R China

[5] Guizhou Med Univ, Key Lab Mol Biol, Minist Educ, Guiyang 550004, Peoples R China

[6] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33612 USA

[7] Third Mil Med Univ, Daping Hosp, Ctr Canc, Chongqing 40042, Peoples R China

[8] Third Mil Med Univ, Res Inst Surg, Ctr Canc, Chongqing 40042, Peoples R China

[9] Univ Texas SouthWestern Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA

[10] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400030, Peoples R China

[11] Univ S Florida, Dept Comp Sci & Engn, Tampa, FL 33620 USA

[12] Huaqiao Univ, Coll Chem Engn, Dept Bioengn & Biotechnol, Xiamen 361021, Fujian, Peoples R China

[13] Zunyi Med Univ, Dept Pediat, Affiliated Hosp, Zunyi 563000, Guizhou, Peoples R China

来源：

AGING-US | 2022年 / 14卷 / 11期

基金：

中国国家自然科学基金;

关键词：

CXCR4; PI3K/Akt/mTOR; CSCs; ovarian cancer; PTX; EPITHELIAL-MESENCHYMAL TRANSITION; CELL INVASION; CANCER; METASTASIS; OVEREXPRESSION; ACTIVATION; RECEPTORS; PROMOTES; LUNG; AXIS;

D O I：

暂无

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy. EOC control remains difficult, and EOC patients show poor prognosis regarding metastasis and chemotherapy resistance. The aim of this study was to estimate the effect of CXCR4 knockdown-mediated reduction of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) stemness and enhancement of chemotherapy sensitivity in EOC. Mechanisms contributing to these effects were also explored. Our data showed distinct contribution of CXCR4 overexpression by dependent PI3K/Akt/mTOR signaling pathway in EOC development. CXCR4 knockdown resulted in a reduction in CSCs and EMT formation and enhancement of chemotherapy sensitivity in tumor cells, which was further advanced by blocking CXCR4-PI3K/Akt/mTOR signaling. This study also documented the critical role of silencing CXCR4 in sensitizing ovarian CSCs to chemotherapy. Thus, targeting CXCR4 to suppress EOC progression, specifically in combination with paclitaxel (PTX) treatment, may have clinical application value.

引用

页码：4673 / 4698

页数：26

共 50 条

[1] CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma (vol 14, pg 4673, 2022)
Zi, Dan
Li, Qing
Xu, Cheng-xiong
Zhou, Zhi-Wei
Song, Guan-Bin
Hu, Cheng-Bin
Wen, Fang
Yang, Han-Lin
Nie, Lei
Zhao, Xing
Tan, Jun
Zhou, Shu-Feng
He, Zhi-Xu
AGING-US, 2022, 14 (21): : 8876 - 8878
[2] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
Musa, Fernanda
Schneider, Robert
TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
[3] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, Seiji
Kuroda, Hiromasa
Takahashi, Ryoko
Sasano, Tomoyuki
GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
[4] BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway
Liu, Xueke
Xie, Chunmei
Li, Amin
Zhang, Yinci
Liu, Xinkuang
Zhou, Shuping
Shen, Jing
Huo, Zhen
Gao, Weiya
Ma, Yongfang
Xu, Ruyue
Xing, Yingru
Xie, Yinghai
Cai, Shuyu
Tang, Xiaolong
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (12): : 7255 - 7271
[5] Effect of CXCR4 on Apoptosis in Osteosarcoma Cells via the PI3K/Akt/NF-κβ Signaling Pathway
Jiang, Chunming
Ma, Shenglin
Hu, Runlei
Wang, Xuepeng
Li, Maoqiang
Tian, Fei
Jiang, Wu
Zhu, Liulong
Bian, Zhenyu
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 46 (06) : 2250 - 2260
[6] Blockade of CXCR4 promotes macrophage autophagy through the PI3K/AKT/mTOR pathway to alleviate coronary heart disease
Li, Fangqin
Peng, Jin
Lu, Yanlin
Zhou, Ming
Liang, Jingwei
Le, Cuiyun
Ding, Jiuyang
Wang, Jiawen
Dai, Jialin
Wan, Changwu
Wang, Jie
Luo, Peng
Xia, Bing
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 392
[7] CXCR4 enhances invasion and proliferation of bone marrow stem cells via PI3K/AKT/NF-κB signaling pathway
Zhang, Hongxu
Jiang, Chunming
Li, Maoqiang
Wang, Xuepeng
Tian, Fei
Fang, Xiang
Zhu, Liulong
Bian, Zhenyu
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (09): : 9829 - 9836
[8] The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Dobbin, Zachary C.
Landen, Charles N.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8213 - 8227
[9] Exploring the roles of ncRNAs in prostate cancer via the PI3K/AKT/mTOR signaling pathway
Guo, Rongwang
Shi, Liji
Chen, Yonghui
Lin, Canling
Yin, Weihua
FRONTIERS IN IMMUNOLOGY, 2025, 16
[10] CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway
Yin, Xiaohong
Liu, Zhiyong
Zhu, Pan
Wang, Yuelong
Ren, Qingqing
Chen, Hongxu
Xu, Jianguo
JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (06) : 9724 - 9736

← 1 2 3 4 5 →